Kymera Therapeutics (KYMR) Receivables - Other: 2020-2025
Historic Receivables - Other for Kymera Therapeutics (KYMR) over the last 4 years, with Mar 2025 value amounting to $20.0 million.
- Kymera Therapeutics' Receivables - Other rose 885.22% to $20.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $20.0 million, marking a year-over-year increase of 885.22%. This contributed to the annual value of $947,000 for FY2024, which is 75.08% down from last year.
- Per Kymera Therapeutics' latest filing, its Receivables - Other stood at $20.0 million for Q1 2025, which was up 2,011.93% from $947,000 recorded in Q4 2024.
- In the past 5 years, Kymera Therapeutics' Receivables - Other ranged from a high of $20.0 million in Q1 2025 and a low of $135,000 during Q4 2021.
- Its 3-year average for Receivables - Other is $4.6 million, with a median of $3.3 million in 2023.
- In the last 5 years, Kymera Therapeutics' Receivables - Other crashed by 84.23% in 2021 and then spiked by 1,779.26% in 2022.
- Quarterly analysis of 5 years shows Kymera Therapeutics' Receivables - Other stood at $135,000 in 2021, then skyrocketed by 1,779.26% to $2.5 million in 2022, then spiked by 49.78% to $3.8 million in 2023, then crashed by 75.08% to $947,000 in 2024, then soared by 885.22% to $20.0 million in 2025.
- Its Receivables - Other was $20.0 million in Q1 2025, compared to $947,000 in Q4 2024 and $1.3 million in Q3 2024.